Faculty Information |
|
Article types | Original article |
Language | English |
Refereed paper | Refereed |
Title | Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. |
Journal | Formal name:European journal of nuclear medicine and molecular imaging ISSN code:16197089/16197070 |
Domestic / Foregin | Foregin |
Volume, Number, Page | 50(5),pp.1487-98 |
Papers・Author | Kitajima Kazuhiro, Igeta Masataka, Kuyama Junpei, Kawahara Takashi, Suga Tsuyoshi, Otani Tomoaki, Sugawara Shigeyasu, Kono Yumiko, Tamaki Yukihisa, Seko-Nitta Ayumi, Ishiwata Yoshinobu, Ito Kimiteru, Toriihara Akira, Watanabe Shiro, Hosono Makoto, Miyake Hideaki, Yamamoto Shingo, Narita Mitsuhiro, Daimon Takashi, Yamakado Koichiro |
Publication date | 2023/04 |
Papers・Description | PURPOSE: To develop a novel nomogram for determining radium-223 dichloride (Ra-223) treatment suitability for metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS: This Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial was a retrospective multicenter investigation enrolled 258 mCRPC patients in Japan with Ra-223 treatment between June 2016 and August 2020, with bone scintigraphy findings before treatment, clinical data, and survival outcome available. A nomogram was constructed using prognostic factors for overall survival (OS) based on a least absolute shrinkage and selection operator Cox regression model. A sub-analysis was also conducted for patients meeting European Medicines Agency (EMA) guidelines. |
PMID | 36539508 |